Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-Cell lymphoma

BioDrugs

Volumn 25, Issue 1, 2011, Pages 55-61

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Haematological malignancies; Leukaemia; Lymphoma; Rituximab, general.

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; MITOXANTRONE; OXALIPLATIN; PENTOSTATIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG COST; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEVER; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; INFECTION; INFUSION SITE REACTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOCUTANEOUS REACTION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 78651370618     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11206980-000000000-00000     Document Type: Article

References (63)

1. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independentofitsFcfunctions. Clin Cancer Res 2009 Nov 1; 15 (21): 6582-94
2. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009 Mar; 8 (2): 223-35
3. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lym-phoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005 Mar 24; 24 (13): 2121-43
4. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007: 233-42
5. Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2009 Jun; 9 (6): 719-26
6. Vega MI, Huerta-Yepez S, Jazirehi AR, et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005 Dec 8; 24 (55): 8114-27
7. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007 Apr; 62 (1): 43-52
8. Tran L, Huitema ADR, Aarden L, et al. Phamacokinetics of rituximab and the development of antibodies against rituximab in patients with a B-cell CD20+ malignancy [abstract no. 0975]. 14th Congress of the European Hematology Association; 2009 Jun 4-7; Berlin
9. Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008 Jan; 3 (1): 22-30
10. Li J, Levi M, Charoin J-E, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin's lymphoma (NHL) patients [abstract no. 2371]. Blood 2007 Nov 16; 110 (11 Pt 1): 700
11. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
12. Robak T, Dmoszynska A, Solal-Celigny P. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fluda-rabine and cyclophosphamide alone in previously treated chronic lympho-cytic leukemia. J Clin Oncol 2010 Apr 1; 28 (10): 1756-65
13. Del Poeta G, Del Principe MI, Maurillo L, et al. Oral fludarabine plus rituximab result in high complete remission rate in B-cell chronic lymphocytic leukemia [abstract no. 0094]. Haematologica 2008 Jun 1; 93 Suppl. 1: 37
14. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 205]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
15. Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in pre-viously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract no. 3428]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
16. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical ac-tivity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109 (2): 405-11
17. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009 Sep 20; 27 (27): 4578-84
18. Faderl S, Wierda W, O'Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 2010 Mar; 34 (3): 284-8
19. Frankfurt O, Hamilton E, Duffey S, et al. Alemtuzumab and rituximab combination therapy for patients with untreated CLL: a phase II trial [abstract no. 2098]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
20. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008 Oct 15; 113 (8): 2110-8
21. Parikh SA, Keating M, O'Brien S, et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rit-uximab (CFAR) in high-risk chronic lymphocytic leukemia [abstract no. 208]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
22. Wierda WG, O'Brien S, Ferrajoli A, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regi-men for high-risk patients with CLL [abstract no. 628]. Blood 2007 Nov 16; 110 (11 Pt 1): 194a
23. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leu-kemia. Leukemia 2009 Oct; 23 (10): 1779-89
24. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract no. 330]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
25. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lympho-cytic leukemia. J Clin Oncol 2008 Jan 10; 26 (2): 196-203
26. Tsimberidou A-M, Wierda W, Plunkett W, et al. Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS) [abstract no. 3443]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
27. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 Apr 1; 24 (10): 1575-81
28. Lamanna N, Heaney ML, Brentjens RJ, et al. Pentostatin, cyclophosphamide, rituximab, and mitoxantrone: a new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR [abstract no. 3115]. Blood 2007 Nov 16; 110 (11 Pt 1): 916
29. Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukaemia recurrence. Cancer 2010 Mar 15; 116 (10): 2360-5
30. Badoux XC, Keating M, O'Brien S, et al. Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL) [abstract no. 3431]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
31. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leu-kemia including those with unfavorable cytogenetic features. Leuk Lym-phoma 2007 Dec; 48 (12): 2412-7
32. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with highdose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008 Nov 1; 22 (11): 2048-53
33. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy [letter]. Haematologica 2008 Mar; 93 (3): 475-6
34. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec 1; 106 (12): 3725-32
35. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct 1; 26 (28): 4579-86
36. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon main-tenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007 May 20; 25 (15): 1986-92
37. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 Dec 15; 112 (13): 4824-31
38. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the Sti L (Study Group Indolent Lymphomas, Germany) [abstract no. 405]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
39. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 Apr 1; 27 (10): 1607-14
40. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999 Jun; 17 (6): 1851-7
41. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000 Sep; 18 (17): 3135-43
42. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) antiCD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000 Sep; 79 (9): 493-500
43. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000 Apr; 109 (1): 81-8
44. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 Sep 15; 90 (6): 2188-95
45. Mc Laughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16 (8): 2825-33
46. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or fol-licular non-Hodgkin's lymphoma. Ann Oncol 1999; 10 (6): 655-61
47. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a pro-spective randomized phase 3 intergroup trial. Blood 2006 Nov 15; 108 (10): 3295-301
48. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010 Jun 10; 28 (17): 2853-8
49. Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab Thera International Trial (MInT) Group. Lancet Oncol 2006 May; 7 (5): 379-91
50. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346 (4): 235-42
51. Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP che motherapy in patients with diffuse large B-cell lymphoma [abstractno. 3741]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
52. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 Jun 20; 23 (18): 4117-26
53. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008 Feb; 9 (2): 105-16
54. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul 1; 24 (19): 3121-7
55. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study [abstract no. 406]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
56. Genentech, Inc. Rituxan (rituximab) injection for intravenous use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/ prod ucts/information/pdf/rituxan-prescribing.pdf [Accessed 2010 Mar 22]
57. Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation ofrituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008 Feb; 49 (2): 227-36
58. Ray JA, Carr E, Lewis G, et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value Health 2010 Jun-Jul; 13 (4): 346-57
59. Deconinck E, Miadi-Fargier H, Le Pen C, et al. Cost effectiveness of rituximab maintenance therapy in follicular maintenance therapy in follicular lympho-ma: long-term economic evaluation. Pharmacoeconomics 2010; 28 (1): 35-46
60. Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second re-mission. Clin Lymphoma Myeloma 2008 Jun; 8 (3): 166-70
61. Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008; 47 (6): 1029-36
62. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr 15; 103 (8): 1644-51
63. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010; 70 (11): 1445-76